65,437 trials
Myeloma
Primary: Participants Who Had Measurable Disease at Time of Transplant and Achieved a Stringent Complete Remission — 16 Participants
Osteoarthritis · Hip Arthropathy · Shoulder Arthropathy
Primary: Post-operative Blood Loss — 1,062.88; 1,204.60; 933.92 mL
Alzheimers Disease · Postoperative Delirium · Post Operative Cognitive Dysfunction
Primary: Correlation Between Perioperative Change in Cerebrospinal Fluid (CSF) Markers of Alzheimers Disease and Perioperative Cognitive Change — -1.21; -5.09; -0.44 pg/ml
Anovulation
Primary: Endometrial Thickness — 6.6; 9.3 millimeter
HIV · Human Immunodeficiency Virus
Primary: Cell-associated HIV RNA — 1.7; 1.9; 1.6 Fold change
Twin Pregnancy
Primary: Perinatal/Neonatal Mortality and/or Serious Neonatal Morbidity — 60; 52; 24; 17 Participants
Healthy
Primary: Number of Participants With Positive Blood Culture for L. Reuteri — 0; 0 Participants
Presbyopia
Primary: Visual Acuity — -0.01; -0.03; -0.05; 0.06 logMAR
Presbyopia · Astigmatism
Primary: Visual Acuity — -0.08; -0.06; 0.00; -0.01 logMAR
Colorectal Cancer · Neoplasms, Colorectal
Primary: Percentage of Participants With Progression-Free Survival at 16 Weeks After Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU)…
Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
Primary: Base Stage: Geometric Mean Titers for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18: Competitive Luminex Immunoassay (cLIA) — 975.2; 686.6; 807.4; 580.2…
Epilepsy · SUDEP
Primary: Study Recruitment Rate — 3.8 participants/3 months
Metastatic Triple Negative Breast Cancer
Primary: Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) ≥10 — 12.7; 11.6 Months — p=0.0574
Pancreatic Cancer · Non-small Cell Lung Cancer · Esophagogastric Cancer
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events — 100.0; 100.0; 83.3; 100.0 percentage of participants
Prostatic Neoplasms
Primary: Efficacy of Leuprolide Mesylate (LMIS 25mg) — 97.9 Percentage of participants